Results 131 to 140 of about 825,443 (336)

Can a Home-based Cardiac Physical Activity Program Improve the Physical Function Quality of Life in Children with Fontan Circulation? [PDF]

, 2016
Objective Patients after Fontan operation for complex congenital heart disease (CHD) have decreased exercise capacity and report reduced health-related quality of life (HRQOL). Studies suggest hospital-based cardiac physical activity programs can improve
Danduran, Michael E., Earing, Michael G., Ginde, Salil, Jacobsen, Roni M., Mussatto, Kathleen, Neubauer, Jennifer   +5 more
core   +1 more source

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

American Journal of Hematology, EarlyView.
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs, Elizabeth A. Abels, Brian D. Adkins, Garrett S. Booth, Victoria Costa, Sheharyar Raza, Michelle Simon, Jennifer S. Woo, Allison P. Wheeler   +8 more
wiley   +1 more source

Aortic valve neo-cuspidation using the Ozaki technique for acquired and congenital disease: where does this procedure currently stand? [PDF]

Indian J Thorac Cardiovasc Surg, 2020
Baird CW, Marathe SP, Del Nido PJ.
europepmc   +1 more source

Plasma HGF and OPN as Potential Biomarkers of Pulmonary Arterial Hypertension in Congenital Heart Disease

, 2021
Dongdong Zheng, Chi Shen, Wenshi Liu, Wenjing Lv, Xiaofei Li   +4 more
openalex   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

American Journal of Hematology, EarlyView.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang, Ruonan Li, Qian Liang, Weiwang Li, Hong Pan, Zhen Gao, Liwei Fang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Jun Li, Hong Zhang, Jun Shi   +18 more
wiley   +1 more source

Initial clinical experience with dapagliflozin in addition to optimized medical therapy in paediatric heart failure patients

ESC Heart Failure
Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT2) inhibitor, has shown clinical benefits in adults with heart failure (HF), improving cardiac function, reducing HF‐related hospitalizations and enhancing survival rates.
Lisa‐Maria Rosenthal, Oliver Miera, Annemarie Krauss, Friederike Danne, Felix Berger, Peter Kramer   +5 more
doaj   +1 more source

Surgical Ventricular Septal Defect Repair

JACC: Case Reports
Ventricular septal defects (VSDs), the most common of congenital heart defects, vary widely in anatomy and size. Surgical treatment of very large VSDs can be challenging because no clear recommendations exist about which defects can undergo biventricular
Emmanuelle Fournier, MD, Bastien Provost, MD, Alice Dirickx, MD, Estibaliz Valdeolmillos, MD, Gregoire Albenque, MD, Clément Batteux, MD, Viktoria Weixler, MD, PhD, Sébastien Hascöet, MD, PhD, Emre Belli, MD, PhD   +8 more
doaj   +1 more source

Convalescent Immunity to Guinea Pig Cytomegalovirus Induces Limited Cross Strain Protection against Re-Infection but High-Level Protection against Congenital Disease. [PDF]

Int J Mol Sci, 2020
Choi KY, El-Hamdi NS, McGregor A.
europepmc   +1 more source

Advances in the Congenital Heart Disease

, 2023
Norihiko Oka
openalex   +2 more sources

Congenital Heart Disease [PDF]

Postgraduate Medical Journal, 1945
openaire   +3 more sources